Production (Stage)
Xeris Biopharma Holdings, Inc.
XERS
$4.83
-$0.05-1.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -80.32% | 67.51% | -4.89% | 20.94% | -41.75% |
| Total Depreciation and Amortization | 0.32% | 0.29% | -0.95% | -1.87% | -1.38% |
| Total Amortization of Deferred Charges | 2.43% | 2.62% | -0.50% | 40.84% | 8.73% |
| Total Other Non-Cash Items | 23.25% | 27.30% | -30.64% | 680.69% | 219.95% |
| Change in Net Operating Assets | -1,849.58% | -170.33% | 119.90% | 39.87% | -132.17% |
| Cash from Operations | -607.90% | 123.78% | 19.74% | 49.03% | -371.76% |
| Capital Expenditure | 94.09% | -152.87% | 78.09% | -142.07% | -24.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 2.35% | 100.02% | 125.66% | -229.91% |
| Cash from Investing | -100.13% | 1.03% | 115.38% | 123.42% | -232.16% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | 200.00% | -- | -- |
| Issuance of Common Stock | 761.88% | -- | -100.00% | 54.68% | -- |
| Repurchase of Common Stock | -4,718.07% | -100.00% | -62.75% | 98.51% | -6,908.16% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -200.00% | 200.00% | -898.40% |
| Cash from Financing | -888.19% | 579.52% | -112.59% | -98.13% | 2,952.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -206.39% | 711.86% | 130.00% | -6.87% | -122.55% |